CORRECTED: Genentech Sinks Bid For AIA Review Of Cancer Drug Patent
The Patent Trial and Appeal Board on Tuesday declined to institute an inter partes review of a Genentech Inc. and ImmunoGen Inc. patent for the cancer treatment Kadcyla, finding it was...To view the full article, register now.
Already a subscriber? Click here to view full article